Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics (NASDAQ: ACRS) has announced inducement grants under NASDAQ Listing Rule 5635(c)(4). The company's Compensation Committee granted 215,000 nonstatutory stock options and 61,000 restricted stock units to one new employee under their 2024 Inducement Plan.
The stock options have an exercise price of $2.48 per share, matching Aclaris' common stock closing price on January 2, 2025. Both the options and restricted stock units will vest in four equal annual installments of 25% each, starting from the grant date, contingent on continued employment. These equity awards were granted as material inducements for the new employee joining Aclaris, in compliance with NASDAQ rules.
Aclaris Therapeutics (NASDAQ: ACRS) ha annunciato concessioni di incentivo secondo la Regola 5635(c)(4) del NASDAQ. Il Comitato per la Remunerazione dell'azienda ha concesso 215.000 opzioni su azioni non statutarie e 61.000 unità di azioni vincolate a un nuovo dipendente nell'ambito del loro Piano di Incentivo 2024.
Le opzioni su azioni hanno un prezzo di esercizio di $2,48 per azione, equivalente al prezzo di chiusura delle azioni ordinarie di Aclaris del 2 gennaio 2025. Sia le opzioni che le unità di azioni vincolate si matureranno in quattro rate annuali uguali del 25% ciascuna, a partire dalla data di concessione, a condizione di un impiego continuato. Questi premi azionari sono stati concessi come incentivi materiali per il nuovo dipendente che si unisce ad Aclaris, in conformità con le regole del NASDAQ.
Aclaris Therapeutics (NASDAQ: ACRS) ha anunciado concesiones de incentivo bajo la Regla de Cotización 5635(c)(4) de NASDAQ. El Comité de Compensación de la empresa otorgó 215,000 opciones sobre acciones no estatutarias y 61,000 unidades de acciones restringidas a un nuevo empleado bajo su Plan de Incentivo 2024.
Las opciones sobre acciones tienen un precio de ejercicio de $2.48 por acción, coincidiendo con el precio de cierre de las acciones comunes de Aclaris el 2 de enero de 2025. Tanto las opciones como las unidades de acciones restringidas se consolidarán en cuatro cuotas anuales iguales del 25% cada una, comenzando desde la fecha de concesión, condicionadas al empleo continuo. Estas concesiones de capital se otorgaron como incentivos materiales para el nuevo empleado que se une a Aclaris, cumpliendo con las normas de NASDAQ.
Aclaris Therapeutics (NASDAQ: ACRS)는 NASDAQ 상장 규칙 5635(c)(4)에 따라 유인 보상을 발표했습니다. 회사의 보상 위원회는 215,000개의 비정상 주식 옵션과 61,000개의 제한된 주식 단위를 2024 유인 계획에 따라 신규 직원에게 부여했습니다.
주식 옵션의 행사지가는 주당 $2.48로, 2025년 1월 2일 Aclaris의 보통주 마감 가격과 일치합니다. 옵션과 제한된 주식 단위 모두 부여일로부터 시작하여 25%씩 네 번의 동등한 연간 할부로 분배되며, 지속적인 고용이 조건입니다. 이러한 주식 보상은 NASDAQ 규정에 따라 Aclaris에 합류하는 신규 직원에게 주는 실질적인 유인으로 부여되었습니다.
Aclaris Therapeutics (NASDAQ: ACRS) a annoncé des concessions d'incitation selon la Règle de Cotation 5635(c)(4) du NASDAQ. Le Comité de Rémunération de la société a accordé 215 000 options d'achat d'actions non statutaires et 61 000 unités d'actions restreintes à un nouvel employé dans le cadre de son Plan d'Incitation 2024.
Les options d'achat d'actions ont un prix d'exercice de 2,48 $ par action, correspondant au prix de clôture des actions ordinaires d'Aclaris au 2 janvier 2025. Les options et les unités d'actions restreintes seront acquises en quatre versements annuels égaux de 25 % chacun, à compter de la date d'octroi, sous réserve d'une poursuite d'emploi. Ces attributions d'équité ont été accordées comme incitations matérielles pour le nouvel employé rejoignant Aclaris, conformément aux règles du NASDAQ.
Aclaris Therapeutics (NASDAQ: ACRS) hat Anreize gemäß NASDAQ Listungsregel 5635(c)(4) angekündigt. Der Vergütungsausschuss des Unternehmens hat 215.000 nicht-statutäre Aktienoptionen und 61.000 eingeschränkte Aktieneinheiten an einen neuen Mitarbeiter im Rahmen ihres Anreizplans 2024 gewährt.
Die Aktienoptionen haben einen Ausübungspreis von $2,48 pro Aktie, was dem Schlusskurs der Aclaris Stammaktien am 2. Januar 2025 entspricht. Sowohl die Optionen als auch die eingeschränkten Aktieneinheiten werden in vier gleichmäßigen jährlichen Raten von jeweils 25% fällig, beginnend mit dem Datum der Gewährung, abhängig von der weiteren Beschäftigung. Diese Eigenkapitalvergünstigungen wurden als wesentliche Anreize für den neuen Mitarbeiter gewährt, der zu Aclaris wechselt, gemäß den NASDAQ-Vorschriften.
- None.
- None.
WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris’ Board of Directors (the Committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employee under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the new employee becoming an employee of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
The options have an exercise price of
Aclaris Therapeutics Contact:
investors@aclaristx.com
FAQ
What is the exercise price of ACRS stock options granted on January 2, 2025?
How many shares were included in ACRS's January 2025 inducement grants?
What is the vesting schedule for ACRS's January 2025 inducement grants?
Under which plan were ACRS's January 2025 inducement grants issued?
